Risperidone belongs to the group antipsychotics, just like agents such as Dipiperon (pipamperone). These medications work by blocking, among other things dopamine and serotonin receptors, including the 5-HT2A receptor. Precisely that 5-HT2A receptor is the main target site for psychedelics such as psilocybin (truffles), LSD, and also partially MDMA.

That means two things:

1. The psychedelic effects are severely suppressed or even absent altogether. when you use risperidone. So you would hardly notice anything of the psychedelic session, even at higher doses.

2. The use of antipsychotics is a contraindication for psychedelic therapy. Not only because of the interactions, but primarily because someone who needs this type of medication often has an increased susceptibility to psychosis or other psychiatric complaints. Combining them can therefore entail risks.

We wrote earlier that antipsychotics such as Dipiperon (and consequently risperidone) block the effects of psilocybin, and that their use is often a sign that psychedelic therapy is not suitable or safe.

In concrete terms, this means that you you cannot continue using risperidone if you want to do psychedelic therapy. First, you should discuss with your treating physician whether and how the medication can be safely tapered off. This is only responsible under medical supervision. In addition to the potential interactions of the medication, a doctor must also assess whether the individual is prone to psychosis, which is a contraindication for the use of psychedelics and may also be an indication for the use of this antipsychotic.

Risperidone is an atypical (second-generation) antipsychotic that primarily blocks dopamine D₂ and serotonin 5‑HT₂A receptors. It is used for schizophrenia, bipolar disorders, and aggression/irritability (including in autism). Through D₂ blockade, it reduces dopaminergic activity in limbic systems (positive psychotic symptoms) and can counteract paranoia or hallucinations. Risperidone has a very high affinity for 5-HT₂A (approximately 10–20 times greater than for D₂), and additionally blocks α₁-adrenergic and, to a lesser extent, H₁- and α₂-receptors. Symptoms such as sedation, weight gain, orthostatic hypotension, or elevated prolactin levels are partly associated with these side effects. Risperidone is primarily converted in the liver via CYP2D6 to the active metabolite 9-hydroxyrisperidone (paliperidone). Consequently, individuals with reduced CYP2D6 activity (poor metabolizers) may have higher risperidone levels.

Effects of MDMA

MDMA (ecstasy) is an empathogenic/entactogenic amphetamine derivative. It reverses the action of monoamine transporters: it stimulates the release of primarily serotonin (via SERT), and to a lesser extent dopamine (DAT) and norepinephrine (NET). MDMA opens vesicular monoamine storage sites (via VMAT2), causing a sharp increase in intrasynaptic serotonin (and catecholamines). This results in feelings of euphoria, empathy, connectedness, and reduced anxiety. In physics, it leads to tachycardia, hypertension and hyperthermia, bruxism, sweating, and other sympathetic effects. MDMA itself also has some affinity as an agonist for various 5-HT receptors (including 5-HT₁A, 5-HT₂A) and adrenergic receptors. In the liver, MDMA is broken down primarily by CYP2D6 into inactive metabolites (including HMMA). It is important that MDMA is strong CYP2D6 inhibits (auto-inhibition), which leads to non-linear pharmacokinetics: higher doses lead to relatively higher blood levels.

Effect of psilocybin

Psilocybin is a classic psychedelic tryptamine derived from magic mushrooms. After ingestion, psilocybin is rapidly converted into the active psilocin (through dephosphorylation). Psilocin acts primarily as a powerful agonist on the 5-HT₂A receptor (and to a lesser extent on other serotonergic subtypes). This causes the changes in perception and consciousness that are characteristic of psychedelic drugs. The effects begin about 20–40 minutes after ingestion, peak after 60–90 minutes, and last approximately 4–6 hours. Under the influence, one experiences (visual) hallucinations, altered spatial/self-perception, and emotional highs and lows. Psilocybin/psilocin itself does not have a strong reuptake-inhibiting effect; it does not sustainably increase serotonin levels like MDMA. Psilocybin is metabolized via dephosphorylation, subsequent glucuronidation (UGT enzymes), and degradation by monoamine oxidase (MAO). No major CYP interactions are known for psilocybin.

Risperidone affects MDMA

Pharmacodynamically, risperidone and MDMA will act antagonistically. MDMA's euphoric effects are partly dependent on dopamine release and 5-HT₂A activation. Risperidone blocks these receptors, so that much of the effect of MDMA can be diminished. Animal studies clearly show that risperidone suppresses MDMA effects: in mice, risperidone inhibited the development of MDMA-conditioned preference, suggesting that MDMA's rewarding (pleasure-enhancing) effect is diminished. Risperidone also prevents hyperthermia in rats after MDMA injection. This experimental work indicates that risperidone suppresses both serotonergic and dopaminergic overactivation caused by MDMA.

In practice, someone on risperidone who takes MDMA would likely feel much less effect (less euphoria, empathy, hallucinations) and might instead experience a sense of dysphoria or anxiety. Comparative research with haloperidol (a D₂ antagonist) showed that combined administration of haloperidol and MDMA even led to increased anxiety and reduced well-being. Risperidone, with its strong 5-HT₂A blockade, may well make that effect even more extreme. No randomized studies in humans are known, but these pharmacological predictions are supported by animal models and by the fact that antipsychotics are used in the clinic to curb a “bad trip” with MDMA or other psychedelics.

Regarding safety: in large doses, MDMA can cause hyperthermia, increased blood pressure, or cardiac arrhythmias. Risperidone, on the other hand, reduces that rise in temperature. Large registries have indicated that MDMA use with risperidone not is associated with higher mortality – in the available FAERS data, MDMA+risperidone did not result in a fatal outcome in a single case. Moreover, MDMA is rarely the sole agent in serotonic toxidrome: risperidone, through 5-HT₂A antagonism, should actually reduce the risk of serotonin syndrome. (Indeed, in the FAERS study, all reported SS cases involved MDMA together with other serotonergic agents, and risperidone did not occur as the primary cause of SS.) However, one must consider contrasting cardiovascular effects: risperidone can actually cause hypotension or bradycardia, whereas MDMA is stimulating. Such opposing effects can be unpredictable at high doses. In summary: risperidone will likely largely block or reduce MDMA effects, and clinical reports do not indicate additional dangerous interactions. Only an unpredictable combination of sedation (risperidone) and stimulation (MDMA) can lead to unexpected side effects (e.g., fainting or confusion).

Risperidone affects psilocybin

With psilocybin, the effect of risperidone is clear and strongly reducing. Since psilocybin/psilocin acts primarily via 5-HT₂A agonism, risperidone counteracts this by blocking 5-HT₂A. Clinical research confirms this: in a double-blind crossover study in healthy subjects, 0.5–1 mg of risperidone reduced the intensity of almost all subjective effects of psilocybin. For instance, under risperidone, the 'oceanic boundlessness' feeling (security, connectedness) and visual changes decreased significantly. Mental slowing (slower reaction time) caused by psilocybin was also reduced. In practice, someone who is on risperidone and uses magic mushrooms would likely no experience a characteristic trip; the experience is severely flattened or even completely blocked. Risperidone can actually cause sedation, potentially leaving the person only drowsy or confused.

In short, risperidone inhibits the hallucinogenic effects of psilocybin almost completely. This is consistent with older research in which chlorpromazine or haloperidol (also D₂/5-HT₂A antagonists) significantly reduced the psychedelic effect. There are no known adverse safety signals associated with this combination: risperidone can actually be life-saving during a 'bad trip', while risperidone itself does not pose a major serotonergic overdose risk. Instead, concomitant use may primarily result in sedation and confusion.

Hazards and unpredictable effects when combined

Although risperidone dampens MDMA and psilocybin effects, the risk of combination remains. Potential dangers are primarily indirect: someone on risperidone who starts using MDMA may experience unexpectedly severe adverse reactions (e.g., panic or impaired motor skills) because the normal observable effects are suppressed. This can lead to taking higher doses of MDMA to feel something, with all the associated dangers (cardiac stress, exhaustion). Conversely, someone on risperidone who takes psilocybin may not feel a trip but still tremble with fear or confusion.

A theoretical risk is that antipsychotics may precipitate neuroleptic malignancy syndrome (NMS) upon sudden ingestion of a stimulant such as MDMA (or psilocybin after discontinuation of risperidone), although there are no case reports to support this. Serotonin syndrome appears unlikely with this combination: MDMA alone and risperidone (a 5-HT₂A antagonist) would actually provide relief of serotonergy. However, combined muscle tension and hyperthermia may occur if MDMA induces high doses, while risperidone impairs coordination. The dangers of combining substances usually involve the known risks of each individual drug: MDMA can cause dehydration or hyponatremia, and psilocybin can induce extreme anxiety. Risperidone primarily adds sedation, changes in heart rate (α₁ effect), and additional cognitive delay.

There are no large case series or reports of serious incidents specifically involving MDMA+risperidone or psilocybin+risperidone. Retrospective analyses show that MDMA use with risperidone in registered cases was actually not associated with a fatal outcome. Moreover, risperidone is generally used in clinical practice to treat a psychedelic crisis. The literature described is limited to the aforementioned studies (research by Rem et al., Vollenweider et al., etc.).

Available literature on these combinations

Most data come from experimental research and review studies. Animal studies show that risperidone dampens MDMA effects (less hyperthermia and reward). No RCT has been conducted on MDMA + risperidone in humans, but comparative research with haloperidol shows more anxiety symptoms. There is one review study on MDMA + risperidone in clinical practice in which no excess mortality was found. Psilocybin + risperidone has been examined in controlled research: Vollenweider et al. 1998 clearly showed that 0.5–1 mg risperidone strongly reduces subjective psychedelic effects. Systematic reviews of interactive effects (Sarparast et al., 2022) describe these findings. There is little other clinical literature; two expert meta-analyses point out that 5-HT₂A antagonists cancel out the trip. There are no reported case reports of serious side effects resulting solely from the combination with risperidone.

Pharmacokinetic interactions

There are indications of a possible CYP interaction: risperidone and MDMA are both metabolized primarily via CYP2D6. MDMA strongly inhibits CYP2D6 (auto-inhibition), which can lead to increased risperidone concentrations if they are taken concurrently. Conversely, heavy use of risperidone (particularly in individuals with limited CYP2D6) could delay the breakdown of MDMA, thereby increasing the duration or toxicity of MDMA. This is analogous to known interactions between MDMA and CYP2D6 inhibitors (such as fluoxetine), where MDMA exposure increases. There are no reports regarding risks specific to risperidone as a 2D6 substrate, but it is known from pharmacogenetics that poor metabolizers risperidone can accumulate to a higher level. Practically, this means that concomitant use can lead to increased or prolonged effects of both substances. A second point is that MDMA and risperidone influence prolactin and adrenaline levels, etc., but no clear clinical interaction is known regarding this.

Psilocybin is not broken down via CYP2D6, so little pharmacokinetic interaction is to be expected for risperidone + psilocybin. Risperidone will pharmacodynamically block the action of psilocybin, but risperidone levels are not significantly affected by psilocybin, and vice versa.

In summary: Risperidone inhibits the psychotropic effects of MDMA and psilocybin through D₂/5-HT₂A blockade. As a result, the intended euphoric and hallucinogenic effects are attenuated. Caution is advised with concomitant use: after suppressed subjective experiences, one may be inclined to take higher doses, which poses risks (cardiac strain, dehydration, potential serotonin syndrome if other serotonergic agents are involved). However, in the available literature, combination with risperidone does not lead to serious or unexpected toxic effects. Pharmacokinetically, co-ingestion can increase the blood levels of each agent via shared metabolism (CYP2D6), which may potentiate the sedative and cardiovascular side effects.